Neil H. Shusterman - Concepedia

Author

Neil H. Shusterman

Also Known As

N H Shusterman, N Shusterman, N. H. Shusterman, N. Shusterman, N.H. Shusterman, NEIL H. SHUSTERMAN, NEIL SHUSTERMAN, Neil H. Shusterman, Neil Shusterman

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

New Frontier University of Pennsylvania Hospital of the University of Pennsylvania The University of Texas Southwestern Medical Center Stanford University

About

Neil H. Shusterman is an author at New Frontier specializing in medicine, nephrology, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1.5K
2	Engineering	1	1	38
3	Health Sciences	1	1	44
4	Public Health	1	1	125
5	Environmental Engineering	1	1	38

Neil H. Shusterman

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure Milton Packer, Michael R. Bristow, Jay N. Cohn, New England Journal of Medicine	1996	4.7K
Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure Milton Packer, Wilson S. Colucci, Jonathan Sackner‐Bernstein, Circulation	1996	615
Risk factors and outcome of hospital-acquired acute renal failure Neil H. Shusterman, Brian L. Strom, Thomas G. Murray, The American Journal of Medicine GlomerulonephritisHemodialysisRenal DiseaseMedicineKidney Failure	1987	367
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism Andrew Wang, Terry L. Holcslaw, Thomas M. Bashore, Kidney International Endothelin Receptor AntagonismMedicinePhysiologyEndothelial DysfunctionVascular Biology	2000	232
Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function Neil H. Shusterman, W.J. Elliott, William B. White The American Journal of Medicine HypertensionUrologyRenal FunctionHypertensive PatientsMedicine	1993	135
Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program José A. Joglar, Andre Acusta, Neil H. Shusterman, American Heart Journal Heart FailureStructural Heart DiseaseCardiovascular DiseaseRetrospective AnalysisCardiac Care	2001	125
The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency T. W. B. Gehr, David M. Tenero, D. A. Boyle, European Journal of Clinical Pharmacology HypertensionCardiovascular DiseaseRenal InsufficiencyMedicineAntihypertensive Therapy	1999	113
Successful use of double-lumen, silicone rubber catheters for permanent hemodialysis access Neil H. Shusterman, K Kloss, James L. Mullen Kidney International HemodialysisUrologyPermanent Hemodialysis AccessMedicineVascular Surgery	1989	105
The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial David R. Holmes, Peter J. Fitzgerald, Sheldon Goldberg, American Heart Journal Preventive MedicineClinical EffectivenessPatient SafetyClinical TrialsOutcomes Research	2000	77
Fatal Massive Hepatic Necrosis in Cytomegalovirus Mononucleosis Neil H. Shusterman Annals of Internal Medicine ImmunodeficienciesImmunologyPathologyCytomegalovirus MononucleosisImmune System	1978	52

Page 1